A study: ‘SATB2 loss and the immune milieu of colorectal cancer (CRC)’ was presented by Dr Darran O’ Connor, a cancer biologist at the Royal College of Surgeons Ireland at the Gastrointestinal (Colorectal) Cancer session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Findings conclude that SATB2 acts as a master regulator of inflammation in the gut, and the loss of expression is significantly associated with the progression of colorectal cancer.
The 2018 ASCO Annual Meeting offered informative educational and scientific sessions that highlighted the latest in cancer care treatments. The meeting took place from 1-5 June 2018 in Chicago, IL, USA.
Abstract citation: J Clin Oncol 36, 2018 (suppl; abstract 3569). For more information on this study and the other researchers involved, please click here.